Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Cancer Biotech Raising $147 Million in IPO

(A. Kotok)

30 April 2015. Blueprint Medicines, a developer of cancer therapies that block enzymes supporting tumor growth, is raising some $146.7 million in its initial public stock offering. The Cambridge, Massachusetts enterprise, listed on the NASDAQ exchange under the symbol BPMC, issued 8.15 million shares at $18.00.

The company began trading today with . . . → Read More: Cancer Biotech Raising $147 Million in IPO

Phone Add-On Designed to Image DNA Molecules

Aydogan Ozcan (UCLA)

30 April 2015. A bioengineering lab at University of California in Los Angeles is developing a smartphone attachment that can image and measure the length of DNA molecules. The team led by engineering professor Aydogan Ozcan is scheduled to describe the system on 14 May at the Conference on Lasers and . . . → Read More: Phone Add-On Designed to Image DNA Molecules

Taking a break

(rhythmuswege/Pixabay)

16 April 2015. We will be traveling for the next two weeks, to recharge our batteries and see some of the world beyond beyond science and business. Regular posting will resume on 30 April.

* * *

Please share Science & Enterprise …

Plant Science Biotech Gets Genome Editing Technology

Dan Voytas (Cellectis Plant Sciences)

16 April 2015. Cellectis Plant Sciences, a biotechnology company in Minnesota developing higher quality crops through genetic engineering, licensed CRISPR genome editing technology from University of Minnesota. Financial details of the agreement between Cellectis and the university were not disclosed.

The technology licensed by Cellectis covers techniques known as . . . → Read More: Plant Science Biotech Gets Genome Editing Technology

Aduro Biotech Raises $108 million in IPO

Listeria bacteria (CDC.gov)

15 April 2015. Aduro Biotech Inc., a developer of immunotherapies to treat cancer, issued its initial public stock offering today that expects to net the company some $108 million, after issuing 7 million shares priced at $17.00. The Berkeley, California enterprise trades on the Nasdaq exchange under symbol ADRO. As of . . . → Read More: Aduro Biotech Raises $108 million in IPO

Trial Shows Multiple Sclerosis Drug Improves Optic Nerves

(NIH.gov)

15 April 2015. A clinical trial testing a new therapy for multiple sclerosis shows the drug improves the performance of optic nerves in patients with acute optic neuritis, a condition highly associated with multiple sclerosis. Researchers from the biotechnology company Biogen present their findings next week at the annual meeting of American Academy . . . → Read More: Trial Shows Multiple Sclerosis Drug Improves Optic Nerves

Smart Treadmill Adjusts to Running Speed Changes

Steven Devor, right, with automated treadmill during tests of the system (Ohio State University)

14 April 2015. Researchers at Ohio State University designed an automated treadmill that adjusts to changes in running speed by users, thus making the experience more like running outdoors. Steven Devor, professor of kinesiology, with former graduate student Cory Scheadler . . . → Read More: Smart Treadmill Adjusts to Running Speed Changes

Trial Testing App to Manage Diabetes, Foot Ulcers

Sugar app, main screen. Click on image for full-size view. (Worcester Polytechnic Institute)

14 April 2015. A clinical trial is getting under way testing a smartphone app to help people with diabetes manage their condition, and in particular assess chronic foot ulcers associated with diabetes. The application is the work of an information technology . . . → Read More: Trial Testing App to Manage Diabetes, Foot Ulcers

Gene Therapy Biotech Raises $60M in Venture Funds

Adeno-associated virus (LBL.gov)

13 April 2015. Voyager Therapeutics, a biotechnology company developing gene therapies for central nervous system disorders, raised $60 million in its second venture financing round. Financing for the 1 year-old enterprise in Cambridge, Massachusetts was led by new investors Brookside Capital and Partner Fund Management, with participation by Wellington Management Company . . . → Read More: Gene Therapy Biotech Raises $60M in Venture Funds

Janssen Licensing DNA Technology for Hep B Vaccine

Transmission electron micrograph of hepatitis B virus particles (Public Health Image Library, CDC)

13 April 2015. Janssen Pharmaceuticals, a division of Johnson & Johnson, is licensing an electronic DNA drug delivery technology from Ichor Medical Systems for vaccines to treat hepatitis B. Ichor, based in San Diego, expects to gain as much as $85 . . . → Read More: Janssen Licensing DNA Technology for Hep B Vaccine